Migraine therapy

HK40137338APending Publication Date: 2026-09-11MEDIMMUNE LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026123963
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-01-25
Filing Date
2026-05-26
Publication Date
2026-09-11

Smart Images

  • Figure 00000053_0000
    Figure 00000053_0000
  • Figure 00000053_0001
    Figure 00000053_0001
  • Figure 00000054_0000
    Figure 00000054_0000
Patent Text Reader

Abstract

The disclosure generally provides compositions and methods that are useful in the treatment of migraine. More specifically, the methods and compositions may be used to treat, alleviate or prevent migraine in subjects who are Inadequate Responders to anti-5 CGRP therapy (aCGRP-IR) or in subjects which are not responsive to anti-CGRP (calcitonin gene-related peptide) therapy or to an inhibitor of calcitonin gene-related peptide (CGRP).
Need to check novelty before this filing date? Find Prior Art

Description

Abstract This disclosure generally provides compositions and methods for the treatment of migraine. More specifically, these methods and compositions can be used to treat, alleviate, or prevent migraine in subjects who are inadequately responsive to 5-CGRP therapy (aCGRP-IR) or who are unresponsive to CGRP (calcitonin gene-related peptide) therapy or inhibitors of calcitonin gene-related peptide (CGRP).

Claims

Claims1 . A method for treating, alleviating or preventing migraine in a subject, the method comprising administering to the subject an antibody or antigen-binding fragment thereof which specifically binds to protease activated receptor 2 (PAR2) and inhibits its activity, wherein the subject is an Inadequate Responder to anti-CGRP therapy (aCGRP-IR) or wherein the subject suffers from migraines which are not responsive to anti-CGRP (calcitonin gene-related peptide) therapy or which are not responsive to an inhibitor of calcitonin gene-related peptide.

2. A method for treating, alleviating or preventing migraine in a subject in need thereof, the method comprising administering to the subject an antibody or antigen-binding fragment thereof which specifically binds to protease activated receptor 2 (PAR2) and inhibits its activity, wherein the subject is intolerant to anti-CGRP (calcitonin gene-related peptide) therapy or to an inhibitor of calcitonin gene-related peptide.

3. The method of claim 1 or 2, wherein the antibody or antigen-binding fragment thereof specifically binds human PAR2.

4. The method of any one of claims 1 to 3, wherein the antibody or antigen-binding fragment thereof prevents cleavage of the PAR2 extracellular domain.

5. The method of claim 4, wherein the antibody or antigen-binding fragment thereof prevents trypsin, tryptase and / or matriptase from cleaving PAR2.

6. The method of claim 5, wherein the antibody or antigen-binding fragment thereof prevents trypsin, tryptase and / or matriptase from interacting with PAR2.

7. The method of any one of claims 1 to 6, wherein the antibody or antigen-binding fragment thereof inhibits exposure of the PAR2 tethered ligand.

8. The method of any one of claims 1 to 7, wherein the antibody or antigen-binding fragment thereof prevents the PAR2 tethered ligand from interacting with the extracellular loop 2 of PAR2.

9. The method of any one of claims 1 to 8, wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody or antigen-binding fragment thereof.

10. The method of claim 9, wherein the antibody is an IgG antibody.11 . The method of any one of claims 1 to 8, wherein the antigen-binding fragment of an antibody is a Fab, Fab’, F(ab’)2 or scFv.

12. The method of any one of claims 1 to 11 , wherein the antibody or antigen-binding fragment thereof is human or humanised.

13. The method of any one of claims 1 to 12, wherein the antibody or antigen-binding fragment thereof binds to PAR2 with a greater affinity at pH 7.4 than at pH 6.

14. The method of claim 13, wherein the antibody or antigen-binding fragment thereof:(i) binds to PAR2 at pH 7.4 with a KD of less than about 5 nM, 1 nM, 900 pM, 800 pM, 700 pM, 650 pM, 600 pM, 500 pM, 200 pM, 100 pM or 50 pM; and / or(ii) binds to PAR2 at pH 6 with a KDof more than about 1 nM, 5 nM, 10 nM, 15 nM, 20 nM, 25 nM, 30 nM, 40 nM, 50 nM, 60 nM, 80 nM, or 100 nM.

15. The method of any one of claims 1 to 14, wherein the antibody or antigen-binding fragment thereof specifically binds to the amino acid sequence set forth in SEQ ID NO: 11 .

16. The method of any one of claims 1 to 15, wherein the antibody or antigen-binding fragment thereof comprises CDRs as follows:VLCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 1 ;VLCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 2;VLCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 3;VHCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 4;VHCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 5;VHCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 6.

17. The method of claim 16, wherein the antibody or antigen-binding fragment thereof comprises:(i) aHdomain comprising the amino acid sequence set forth in SEQ ID NO: 7, or an amino acid sequence with at least 70 %, 80 % or 90 % sequence identity thereto; and(ii) a L domain comprising the amino acid sequence set forth in SEQ ID NO: 8, or an amino acid sequence with at least 70 %, 80 % or 90 % sequence identity thereto.

18. The method of claim 17, wherein the antibody comprises:(i) a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 9, or an amino acid sequence with at least 70 %, 80 % or 90 % sequence identity thereto; and(ii) a light chain comprising the amino acid sequence set forth in SEQ ID NO: 10, or an amino acid sequence with at least 70 %, 80 % or 90 % sequence identity thereto.

19. The method of any one of claims 1 to 18, wherein the subject is an Inadequate Responder to or the subject is not responsive to migraine therapy with or intolerant to an antibody that prevents CGRP binding to and / or activating the CGRP receptor.

20. The method of claim 19, wherein the antibody that prevents CGRP binding to and / or activating the CGRP receptor specifically binds to CGRP or the CGRP receptor.21 . The method of any one of claims 1 to 20, wherein the subject an Inadequate Responder to or is not responsive to migraine therapy with or intolerant of a gepant.

22. The method of any one of claims 1 to 21 , wherein the subject is also not responsive to migraine therapy with a p-blocker (e.g. propanalol), a triptan (e.g. zolmitriptan), topiramate, candesartan, a calcium channel blocker (e.g. flunarizine), a tricyclic antidepressant (e.g. amitriptyline) and / or valproic acid or a salt thereof (e.g. sodium valproate).

23. The method of any one of claims 1 to 22, wherein the antibody or antigen-binding fragment thereof is administered within a pharmaceutical composition comprising at least one pharmaceutically acceptable diluent, carrier or excipient.

24. The method of any one of claims 1 to 23, wherein the subject is a human.

25. An antibody which specifically binds to human PAR2 and inhibits its activity, or an antigen-binding fragment thereof, for use in the treatment, alleviation or prevention of migraine in a subject who is an Inadequate Responder to anti-CGRP therapy (aCGRP-IR) or wherein the subject suffers from migraines which are not responsive to anti-CGRP or which are not responsive to therapy with an inhibitor of calcitonin gene-related peptide (CGRP).

26. An antibody which specifically binds to human PAR2 and inhibits its activity, or an antigen-binding fragment thereof, for use in the treatment, alleviation or prevention of migraine in a subject who is an Inadequate Responder to anti-CGRP therapy (aCGRP-IR) or wherein the subject who suffers from migraines and is intolerant to an anti-CGRP (calcitonin gene-related peptide) therapy or to an inhibitor of calcitonin gene-related peptide (CGRP).

27. The antibody or antigen-binding fragment thereof for use according to claim 25 or 26, wherein the antibody, antigen-binding fragment thereof, subject, administration and / or therapeutic effect are as defined in any one of claims 3 to 24.